All articles by Swagath Bandhakavi
Swagath Bandhakavi
Bio-Thera partners with Dr. Reddy’s for commercialisation of proposed biosimilars
Under the partnership, Bio-Thera will handle the development, manufacturing, and supply of the biosimilars, while Dr. Reddy’s will oversee regulatory approvals and commercial operations in specific countries
Kelun-Biotech’s SKB107 gains approval for bone metastases clinical trials in China
SKB107 is designed to target bone metastases in solid tumours using a small molecule targeting ligand integrated with conjugation technology, a chelator, and a therapeutic radionuclide
Sermonix and Regor to collaborate on advancing breast cancer drug discovery
The collaboration will combine Sermonix’s clinical drug development expertise with Regor’s computational discovery technology to advance metastatic breast cancer treatment
Duke-NUS and NUS Medicine unveil metabolomics research hub in Singapore
Based at Duke-NUS and NUS Medicine, the research centre focuses on metabolomics to enhance disease detection and precision medicine
Novartis gains first FDA approval for Fabhalta in C3 glomerulopathy
The approval enables Fabhalta to reduce proteinuria in patients with C3G, offering the first authorised treatment for the condition
Servier to license Black Diamond’s BDTX-4933 in $780m oncology deal
Servier will lead the clinical development and global commercialisation of BDTX-4933 for multiple indications, including NSCLC, under the agreement
AbbVie’s Elahere demonstrates extended survival in Phase 3 MIRASOL trial
Elahere outperformed investigator’s choice chemotherapy, with patients experiencing a median progression-free survival of 5.59 months compared to 3.98 months with chemotherapy
Mallinckrodt and Endo to merge in $6.7bn stock and cash deal
The merger will unite pharmaceutical brands across various therapeutic areas, including XIAFLEX, Acthar Gel, Terlivaz, SUPPRELIN LA, and AVEED
ViiV Healthcare’s N6LS shows promise in long-acting HIV treatment
The Phase IIb EMBRACE study found that N6LS, when given every four months with long-acting cabotegravir, successfully maintained viral suppression in adults with HIV who were already stable on treatment
Arvinas and Pfizer’s vepdegestrant meets primary endpoint in VERITAC-2 trial
The trial’s primary endpoint was reached as vepdegestrant demonstrated a statistically significant improvement in PFS in the ESR1m population when compared to fulvestrant